SBIR Phase I: Marker Gene Directed Substrates for Cell Regulation

9561199 Naleway这个小企业创新研究第一阶段项目旨在研究开发新化合物的可行性，这些化合物能够利用转化细胞中共同标记基因的表达来控制活组织中细胞的生长和特征。如果成功，这项研究将提供必要的突破，推动重组基因的前景广阔的商业应用。标记基因技术公司将通过制备新的半乳糖苷和头孢菌素结合物来确定这项技术的可行性，这些半乳糖苷和头孢菌素是常见的生长调节剂、药物和酶抑制剂的结合物，用于各种动物细胞或细菌，这些细胞或细菌含有B-半乳糖苷酶(lac-Z)或氨苄西林耐药(B-内酰胺酶，Amp)基因作为基因融合标记。这些新的结合物将提供检测基因融合的创新方法，并在转化细胞中利用这些融合系统来控制细胞的选定生物学特性。新的结合物将在组织培养和体内进行测试，以确定它们在培养中引起特定的和局部的抑制或改善细胞生长的能力，并以细胞或组织特异性的方式传递这些结合物。这项工作将为该项目的下一阶段提供基础，在该阶段中，将在各种商业应用中测试共轭化合物。标记基因技术公司为该项目带来了标记基因研究领域12年的经验。该公司向全球科学界销售各种市场上的基因导向结合物、分子生物学试剂盒和抑制剂。该项目的成功在植物和作物生产、遗传疾病的医疗干预、癌症治疗的免疫辅助治疗以及在细胞培养系统中生产新蛋白质和药物的生物技术生产领域开辟了重要的商业可能性。此外，它还为细胞生物学基础研究提供了新的信息和技术。

9561199 Naleway This Small Business Innovation Research Phase I project aims to investigate the feasibility of developing new compounds capable of utilizing common marker gene expression in transformed cells to control the growth and character of cells in living tissue. If successful, the research will provide breakthroughs needed to advance the promising commercial uses of recombinant genes. Marker Gene Technologies will establish the feasibility of the technology by preparing new galactoside and Cephalosporin conjugates of common growth regulators, drugs and enzyme inhibitors, for administration to a variety of animal cells or bacteria that contain either the B-galactosidase (lac Z) or ampicillin resistance (B-lactamase, amp) genes as gene fusion markers. These new conjugates will provide innovative methods of detecting gene fusion's and utilizing these fusion systems in transformed cells to control selected biological properties of the cells. The new conjugates will be assayed in tissue culture and in vivo for their ability to cause specific and localized inhibition or improvement of cell growth in culture and to deliver these conjugates in a cell- or tissue-specific manner. This work will provide the foundation for the next phase of the project in which the conjugates will be tested in a variety of commercial applications. Marker Gene Technologies brings 12 years of experience in the area of marker gene research to this project. The company sells a variety of market gene-directed conjugates, molecular biology kits, and inhibitors to the worldwide scientific community. The success of this project opens up significant commercial possibilities in the fields of plant and crop production, medical intervention in genetic diseases, immunoadjuvant therapy for cancer treatment, and biotechnological production of new proteins and drugs in cell-culture systems. In addition, it contributes new information and techniques for basic cell-biology research.